Genmab — April 2018

[AaBforever]

A/B læser åbenbart tallene med andre briller på -:(

[AaBforever]

[OHW]

AB jeg tror ikke de tænker så meget!! De spiller på en generel og stor nedtur på aktiemarked som helhed og når det sker, er biotek blandt dem der falder mest.

[E_L]

I think they went a bit early with their press release and breached the embargo. i remember last year was available around 3 to 4PM

[E_L]

makes me feel like a real nerd remembering that

[Her_for_at_lære]

@OHW, skal vi ned og teste 970?

[OHW]

mjjaaa...nok ikke lige nu

[StockBull]

Nu bestaar a/b jo af over 50 forskellige banker m.m og det er jo ikke sikkert alle har laest salgstallene. Med den lave volumen kan en enkelt bank handle kursen ned.

[StockBull]

I det hele taget tvivler jeg paa nogen under a/b paraplyen bruger ret meget tid paa at students genmabs salgstal.

[StockBull]

Studere

[JohnW]

Stadig ingen SH-tal ?!?

[E_L]

https://twitter.com/ASCO/status/989131910436786177 titles will be available soon (between now and 18.00)

[polle1]

You look good, E L

[E_L]

yes Polle, thank you. But normally it is only girls that tell me how good looking I am

[polle1]

[E_L]

the thing is, whenever the stock is trading this stupid i feel the need to check & search for what happened; i should know better after watching it for so long....but it is hard to resist...

[polle1]

I totally agree, I do exactly the same, and can't find anything negative. So, "same procedure as every time" : stay patient

[polle1]

Hvor blev tallene dog af idag ?

[E_L]

This old Ofa study was set to 'completed' (CHOP) With Ofatumumab in Patients With Richter's Syndrome (CHOP-OR) https://clinicaltrials.gov/ct2/show/NCT01171378?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F24%2F2018&rank=1

[E_L]

and this on has some results (still active) Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (COMPLEMENT 1) - https://clinicaltrials.gov/ct2/show/results/NCT00748189?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F24%2F2018&rank=4